[Efficacy of plerixafor in autologous peripheral blood stem cell collection].
Amyloidosis
/ therapy
Antigens, CD34
Benzylamines
Cyclams
Granulocyte Colony-Stimulating Factor
/ pharmacology
Hematopoietic Stem Cell Mobilization
Heterocyclic Compounds
/ pharmacology
Humans
Lymphoma, Non-Hodgkin
/ therapy
Multiple Myeloma
/ therapy
POEMS Syndrome
/ therapy
Peripheral Blood Stem Cells
/ cytology
Retrospective Studies
Transplantation, Autologous
ASCT
PB CD34+
PBSCH
Plerixafor
Journal
[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
17
8
2019
Statut:
ppublish
Résumé
Failure of autologous peripheral blood stem cell collection (PBSCH) can affect the treatment modality for patients with hematological malignancies. The clinical efficacy of plerixafor in PBSCH was analyzed in our institution. The medical records of 61 patients were retrospectively reviewed. The use of plerixafor was determined according to the CD34
Identifiants
pubmed: 31068511
doi: 10.11406/rinketsu.60.165
doi:
Substances chimiques
Antigens, CD34
0
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
Granulocyte Colony-Stimulating Factor
143011-72-7
plerixafor
S915P5499N
Types de publication
Journal Article
Langues
jpn